News
ASC47 is an adipose-targeted, once-monthly subcutaneously (SQ) injected thyroid hormone receptor beta (THRβ) selective small ...
TipRanks on MSN3d
Ascletis Pharma’s ASC47 Shows Superior Efficacy in Obesity Treatment
Ascletis Pharma, Inc. ( ($HK:1672) ) just unveiled an update. Ascletis Pharma Inc. announced promising preclinical results for its ...
ASC47 is an adipose-targeted, ultra-long-acting SQ injected thyroid hormone receptor beta (THRß) selective small molecule agonist, discovered and developed in-house at Ascletis.
The ASC47-103 study, conducted in the U.S., is a randomized, double-blind, placebo-controlled clinical study designed to evaluate the safety, tolerability and preliminary efficacy of single-dose ...
ASC47 is an adipose-targeted, ultra-long-acting SQ injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, discovered and developed in-house at Ascletis.
The ASC47-103 study, conducted in the U.S., is a randomized, double-blind, placebo-controlled clinical study designed to evaluate the safety, tolerability and preliminary efficacy of single-dose, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback